S&P removes drugmaker Wyeth from 2 indices in sign $68B acquisition by Pfizer will go throughOctober 2nd, 2009 S&P removes Wyeth from indices before acquisitionTRENTON, N.J. — In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.
Pfizer's $68 billion buyout of Wyeth gets clearance in Australia, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in AustraliaNEW YORK — Drug developer Pfizer says the Australian Competition and Consumer Commission approved the company's $68 billion buyout of rival Wyeth. Pfizer will divest certain animal health assets in Australia, the New York-based company says.
Pfizer's $68 billion buyout of Wyeth gets clearance in China, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in ChinaNEW YORK — Drug developer Pfizer Inc. said Tuesday China's ministry of commerce approved the company's $68 billion buyout of rival Wyeth.
Wyeth calls for redemption of floating rate convertible senior debenturesAugust 17th, 2009 Wyeth calls for redemption of senior debenturesMADISON, N.J. — Drugmaker Wyeth said Monday it has called for the full redemption of its outstanding floating rate convertible senior debentures due in 2024 on Sept.
Shareholders of Merck, Schering-Plough to vote on combination, would create No. 2 drugmakerAugust 7th, 2009 Merck takeover of Schering-Plough up for voteTRENTON, N.J. — Shareholders will decide Friday whether two New Jersey drug companies will become the world's second-biggest drugmaker.
Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck.
Merck, Schering-Plough shareholders back $41.1 billion combo to create world's No. 2 drugmakerAugust 7th, 2009 Merck, Schering-Plough shareholders OK $41B dealTRENTON, N.J. — Shareholders of drugmakers Merck & Co.
Merck & Co. shareholders OK $41.1 billion acquisition of partner drugmaker Schering-PloughAugust 7th, 2009 Merck shareholders OK Schering-Plough purchaseTRENTON, N.J. — Shareholders of drugmaker Merck & Co.
Drugmaker Wyeth posts 13 percent jump in 2Q profit on cost cutting ahead of Pfizer acquisitionJuly 23rd, 2009 Drugmaker Wyeth posts 13 percent jump in 2Q profitTRENTON, N.J. — Drugmaker Wyeth on Thursday posted a 13 percent jump in second-quarter profit, trouncing Wall Street forecasts, as cost cuts overcame lower sales due to generic competition and the strong dollar.
Drugmaker Pfizer's 2Q profit plunges 19 percent on Wyeth acquisition charges, stronger dollarJuly 22nd, 2009 Drugmaker Pfizer's 2Q profit plunges 19 percentTRENTON, N.J. — Drug giant Pfizer Inc.
98 percent of shareholders of drugmaker Wyeth vote to be acquired by industry giant PfizerJuly 20th, 2009 Wyeth shareholders vote to be acquired by PfizerTRENTON, N.J. — Shareholders of drugmaker Wyeth on Monday voted overwhelmingly to be bought by industry giant Pfizer Inc., pushing aside one of the deal's final hurdles.
Pfizer pulls out of plan to move biotech workers to San Francisco facilityJuly 7th, 2009 Pfizer ends plan San Francisco biotech facilityNEW YORK — Pfizer Inc. is pulling a plan to staff a biotechnology research center in San Francisco and will keep its 100 area employees in South San Francisco.
EU says Pfizer is suggesting changes to Wyeth bid to win regulatory approvalJune 30th, 2009 EU: Pfizer promising changes to Wyeth bidBRUSSELS — U.S. drug maker Pfizer Inc.
Drugmaker Wyeth posts flat 1st-quarter profit, despite sales drop for several key productsApril 29th, 2009 Drugmaker Wyeth posts flat 1st-quarter profitTRENTON, N.J. — Drugmaker Wyeth, which is being acquired by drug giant Pfizer, on Wednesday posted a flat first-quarter profit but beats analysts' expectations, as cost cuts and a lower tax rate offset lower revenue.
Drugmaker Pfizer's Q1 profit dips 2 percent on much lower sales, costs of Wyeth acquisitionApril 28th, 2009 Pfizer profit dips 2 percent, sales fall much moreNEW YORK — Pfizer Inc. posts a 2 percent drop in first-quarter profit, as cost-cutting by the world's largest drugmaker couldn't offset big drops in sales for several medicines.
Loading ...